*The following content is generated by AI and is for reference only.
Tirofiban is a potent, non-peptide antiplatelet agent belonging to the class of glycoprotein IIb/IIIa inhibitors. Its chemical structure is defined by the molecular formula C24H31NO5S and carries the CAS registry number 138067-49-3. This compound functions as a reversible antagonist of the glycoprotein IIb/IIIa receptor on platelets, which serves as the final common pathway for platelet aggregation. By blocking this specific receptor, Tirofiban prevents fibrinogen from binding to activated platelets, thereby inhibiting thrombus formation without directly affecting the coagulation cascade itself.
Clinically, Tirofiban is primarily indicated for the treatment of acute coronary syndromes (ACS), including unstable angina and non-ST-elevation myocardial infarction (NSTEMI). It is frequently administered intravenously in hospital settings, often in conjunction with aspirin and heparin, to reduce the risk of ischemic events such as heart attack or death. The drug is also utilized during percutaneous coronary interventions (PCI) to prevent acute vessel closure and improve procedural outcomes. Due to its rapid onset of action and short half-life of approximately two hours, it allows for precise control over anticoagulation status, making it ideal for high-risk patients requiring immediate antiplatelet therapy.
The pharmacological profile of Tirofiban distinguishes it from other agents in its class through its selective binding affinity and rapid reversibility upon discontinuation. However, the primary safety concern associated with its use is an increased risk of bleeding, necessitating careful patient monitoring and dose adjustment based on renal function and individual clinical factors. While not suitable for oral administration due to poor bioavailability, its intravenous formulation remains a critical tool in modern interventional cardiology. As research continues into novel antithrombotic strategies, Tirofiban maintains its position as a standard-of-care medication for managing severe cardiovascular emergencies where rapid inhibition of platelet aggregation is essential to preserve myocardial tissue and ensure patient survival.